A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors

NCT02025803 | Completed Phase 1

• 1 other identifier: TPU-TAS-114-101
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.

Conditions

Neoplasms

Keywords

Advanced solid tumors

Outcome Measures

Primary Outcomes (1)

• The MTD of TAS-114/ capecitabine (defined as the highest dose level at which less than 33% of the patients experience a Dose Limiting Toxicity (DLT) during the first cycle of treatment); DLTs defined by protocol

  Only drug-related toxicities during the first cycle are considered in the assessment of DLTs.

  First cycle of treatment (ie. 21 days)

Secondary Outcomes (2)

• Pharmacokinetic profiles (peak plasma concentration (Cmax) and area under the plasma concentration versus time curve (AUC) of TAS-114, capecitabine and it's metabolite 5-FU)

  First cycle of treatment (ie. 21 days)

• antitumor activity by tumor assessments according to RECIST criteria

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months

Study Arms (1)

TAS-114/capecitabine

EXPERIMENTAL

See intervention description

Drug: TAS-114/capecitabine

Interventions

TAS-114/capecitabine DRUG

Part 1 (dose-escalation phase): Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated Part 2 (expansion phase): TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle).

TAS-114/capecitabine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provided written consent
• Is 18 years of age or older
• Has histologically or cytologically confirmed advanced, measurable or non-measurable metastatic solid tumors for which the patients have no available therapy to convey clinical benefit Expansion Phase only: The target population should include at least
• patients with breast cancer for whom 5 FU chemotherapy is the standard treatment
• patients with refractory colorectal cancer.
• May have received prior therapies for advanced or metastatic disease
• Expansion Phase only: Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009), ie, has at least one measurable lesion
• Has ECOG performance status 0 or 1 on Cycle 1, Day 1
• Is able to take medications orally
• Has adequate organ function as defined by protocol
• Women of childl-bearing potential must have a negative pregnancy test within 7 days prior to starting the study drug. Beth males and females must agree to adequate birth control if conception is possible during the study and for 6 months after the last dose
• Is willing to and able to comply with scheduled visits and study procedures.

You may not qualify if:

• Has a known DPD deficiency
• Has had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration.
• Certain serious illnesses or medical conditions
• Is receiving concomitant treatment with drugs that may interact with capecitabine
• Has had prior gastrectomy
• Has known sensitivity to capecitabine or metabolites
• Is a pregnant or lactating female

Sponsors & Collaborators

• Taiho Oncology, Inc.: lead
• Quintiles, Inc.: collaborator

Study Sites (3)

USC/Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

Location

IU Simon Cancer Center

Indianapolis, Indiana, 46202, United States

Location

Karmanos Cancer Institute

Detroit, Michigan, 48201, United States

Location

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 27, 2013
• First Posted: January 1, 2014
• Study Start: November 1, 2012
• Primary Completion: July 7, 2017
• Study Completion: July 7, 2017
• Last Updated: September 5, 2024

Record last verified: 2024-08

Locations

US (3)